American College of Rheumatology Encourages Safe Adoption of Biosimilars During FDA Public Hearing on CT-P13, a Proposed Biosimilar for Infliximab (Remicade) ATLANTA, Feb. 10, 2016 (GLOBE NEWSWIRE) -- During a public meeting held Tuesday by the Food and Drug Administration (FDA)'s Arthritis Advisory Committee to review the license application of CT-P13,...